XML 122 R15.htm IDEA: XBRL DOCUMENT
v3.23.3

Intangible Assets | 6 Months Ended | 12 Months Ended
--- | --- | ---
Jun. 30, 2023 | Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract] |  |
Intangible Assets | Note 8. Intangible Assets The definite-lived intangible assets, to be amortized over 20 years, balances, and activity for the six months ended June 30, 2023, year ended December 31, 2022 consisted of the following: Schedule of Intangible Assets
|  | 06/30/2023 |  |  | 12/31/2022 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Definitive-lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  | $ | 22,260,000 |  |  | $ | (2,783,000 | ) |  | $ | 19,477,000 |  |  | $ | 22,260,000 |  |  | $ | (2,226,000 | ) |  | $ | 20,034,000 |
Total |  | $ | 22,260,000 |  |  | $ | (2,783,000 | ) |  | $ | 19,477,000 |  |  | $ | 22,260,000 |  |  | $ | (2,226,000 | ) |  | $ | 20,034,000 |
The following table represents future amortization of developed technologies for the years ending December 31: Schedule of Future Amortization of Developed Technologies
2023 |  | $ | 557,000 |
2024 |  | $ | 1,113,000 |
2025 |  | $ | 1,113,000 |
2026 |  | $ | 1,113,000 |
2027 |  | $ | 1,113,000 |
Thereafter |  | $ | 14,468,000 |
IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements | Note 9. Intangible Assets The definite-lived intangible assets, to be amortized over 20 years, balances and activity for the years ended December 31, 2022, and 2021 consisted of the following: Schedule of Intangible Assets
|  | 12/31/2022 |  |  |  |  |  |  |  |  | 12/31/2021 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |
Definitive-lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Developed technology |  | $ | 22,260,000 |  |  | $ | (2,226,000 | ) |  | $ | 20,034,000 |  |  | $ | 22,260,000 |  |  | $ | (1,113,000 | ) |  | $ | 21,147,000 |
Total |  | $ | 22,260,000 |  |  | $ | (2,226,000 | ) |  | $ | 20,034,000 |  |  | $ | 22,260,000 |  |  | $ | (1,113,000 | ) |  | $ | 21,147,000 |
The following table represents future amortization of developed technologies: Schedule of Future Amortization of Developed Technologies
2023 |  | $ | 835,000 |
2022 |  | $ | 1,113,000 |
2023 |  | $ | 1,113,000 |
2024 |  | $ | 1,113,000 |
2025 |  | $ | 1,113,000 |
2026 |  | $ | 1,113,000 |
Thereafter |  | $ | 14,469,000 |
IMPACT Biomedical, Inc. and Subsidiaries Notes to Consolidated Financial Statements In March 2021, the fair value of the assets acquired by DSS on August 21, 2020, was concluded. An impairment analysis was conducted for financial reporting purposes in connection with U.S. GAAP and ASC 360-10, Impairment and Disposal of Long-Lived Assets. Although the Company has a history of negative cash flows from operations, its financing arrangement with DSS (see Note 9) provides the opportunity to fund ongoing operations. This, as well as there being no other indicators present for impairment, has led management to conclude that no impairment is necessary for the years ended December 31, 2022, and 2021.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350-30/tableOfContent + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration